D.A. Davidson & Co’s Lexicon Pharmaceuticals LXRX Stock Holding History

D.A. Davidson & Co’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-23,550	Closed	-$98K	–	1034
2019 Q4	$98K	Buy	23,550 +2,790	+13%	+$10.7K	﹤0.01%	983
2019 Q3	$62K	Sell	20,760 -2,800	-12%	-$8.67K	﹤0.01%	981
2019 Q2	$148K	Buy	23,560 +2,025	+9%	+$12.1K	﹤0.01%	928
2019 Q1	$120K	Buy	21,535 +8,455	+65%	+$51.4K	﹤0.01%	1078
2018 Q4	$87K	Buy	+13,080	New	+$106K	﹤0.01%	1060
2017 Q3	–	Sell	-4,600	Closed	-$75K	–	1603
2017 Q2	$75K	Sell	4,600 -800	-15%	-$12.4K	﹤0.01%	1375
2017 Q1	$77K	Sell	5,400 -4,825	-47%	-$71.6K	﹤0.01%	1348
2016 Q4	$141K	Buy	10,225 +7,025	+220%	+$113K	﹤0.01%	1151
2016 Q3	$57K	Buy	3,200 +2,400	+300%	+$38.6K	﹤0.01%	1464
2016 Q2	$11K	Buy	+800	New	+$10.8K	﹤0.01%	1934

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

D.A. Davidson & Co's LXRX Position: Q1 2020 in Review

D.A. Davidson & Co sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2020, closing a stake of 23,550 shares — an estimated $98K sold.

D.A. Davidson & Co first reported a position in LXRX in Q2 2016 and held it in 10 quarters. The position peaked at $148K in Q2 2019. 113 funds tracked by Wall St. Rank hold LXRX as of Q1 2020.

D.A. Davidson & Co reported no remaining Lexicon Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
D.A. Davidson & Co sold 23,550 Lexicon Pharmaceuticals shares in Q1 2020, an estimated $98K.
D.A. Davidson & Co first reported a position in Lexicon Pharmaceuticals in Q2 2016 and held it in 10 quarters.
D.A. Davidson & Co's Lexicon Pharmaceuticals position peaked at $148K in Q2 2019.
113 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2020.

Based on D.A. Davidson & Co's 13F filing for Q1 2020, filed 5 May 2020.